Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 298,780 shares, a growth of 528.9% from the May 14th total of 47,507 shares. Based on an average trading volume of 667,164 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the shares of the company are sold short.

Daiichi Sankyo Trading Down 0.6%

DSNKY stock opened at $15.93 on Wednesday. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $27.50. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $17.03 and its 200-day moving average is $19.25. The firm has a market cap of $30.18 billion, a P/E ratio of 16.95, a P/E/G ratio of 1.11 and a beta of -0.16.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The company had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities analysts anticipate that Daiichi Sankyo will post 0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.